Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Holdings Lessened by Ameriprise Financial Inc.

Ameriprise Financial Inc. cut its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 3.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 209,923 shares of the company’s stock after selling 7,166 shares during the period. Ameriprise Financial Inc. owned about 0.14% of Xeris Biopharma worth $712,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of Xeris Biopharma by 166.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company’s stock valued at $3,537,000 after acquiring an additional 651,481 shares in the last quarter. Renaissance Technologies LLC boosted its position in Xeris Biopharma by 31.3% during the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after purchasing an additional 500,120 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in Xeris Biopharma in the fourth quarter valued at about $1,610,000. AIGH Capital Management LLC increased its position in Xeris Biopharma by 17.8% in the 4th quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock worth $8,729,000 after purchasing an additional 389,192 shares during the last quarter. Finally, EAM Investors LLC purchased a new stake in shares of Xeris Biopharma during the 4th quarter worth about $754,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

Shares of XERS opened at $5.05 on Tuesday. The company has a market capitalization of $789.74 million, a PE ratio of -11.22 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a one year low of $2.03 and a one year high of $6.07. The company’s fifty day moving average price is $4.63 and its 200 day moving average price is $4.05.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 40,000 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.47% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on XERS shares. Oppenheimer raised their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Wall Street Zen downgraded shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum raised their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.25.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.